Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is set to present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The company's CEO and Chairman, Dr. Vuong Trieu, will lead the presentation, offering investors an opportunity to engage in a live question-and-answer session. This event comes at a pivotal time for the clinical-stage biotechnology firm, which has been making significant strides in its oncology pipeline and advanced technology platforms.
The presentation will focus on recent progress, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This milestone underscores the company's commitment to developing innovative therapies for cancer and other serious diseases. Additionally, Oncotelic has expanded its European clinical sites, broadening the reach of its studies and potentially accelerating patient enrollment and data collection.
A key highlight of the presentation will be the validation of the Deciparticle™ platform through peer-reviewed publications. This proprietary drug delivery technology is designed to enhance the efficacy and safety of therapeutic agents, and its validation marks an important step in establishing credibility within the scientific community. The company also boasts scalable cGMP manufacturing capabilities, which are essential for transitioning from clinical trials to commercial production.
Oncotelic continues to invest in cutting-edge technologies, including AI-driven drug discovery, robotics, and nanomedicine platforms. These initiatives aim to streamline the development process, reduce costs, and improve patient outcomes. The integration of artificial intelligence in drug discovery is particularly promising, as it can identify potential candidates faster and more efficiently than traditional methods.
Investors interested in learning more about Oncotelic's strategic direction and recent achievements can access the full press release at https://nnw.fm/fGHUt. For ongoing updates and news, the company's newsroom is available at https://nnw.fm/OTLC.
The OTCQB Virtual Investor Conference provides a platform for emerging growth companies to connect with a wide range of investors. Oncotelic's participation highlights its transparency and commitment to keeping stakeholders informed about its progress. As the company continues to advance its pipeline and leverage innovative technologies, its presentation at this conference could attract attention from potential partners and investors looking to support promising oncology developments.
